

Filed on behalf of: Breckenridge Pharmaceutical, Inc.

By: Daniel R. Evans
Registration No. 55,868
MERCHANT & GOULD P.C.
191 Peachtree Street, NE
Suite 3800
Atlanta, GA 30303
Main Telephone: 404.954.5100
Main Facsimile: 612.332.9081

UNITED STATES PATENT AND TRADEMARK OFFICE BEFORE THE

PATENT TRIAL AND APPEAL BOARD

BRECKENRIDGE PHARMACEUTICAL, INC.

Petitioner, v.

NOVARTIS PHARMACEUTICALS CORPORATION

Patent Owner.

Case: IPR2017-01592
U.S. Patent No. 8,410,131

**NOTICE OF JOINT STIPULATION TO
MODIFY TRIAL DUE DATE 2**

IPR2018-00507 has been joined to this proceeding (Paper 29, Apr. 03, 2018)

Pursuant to the Board’s authorization in the January 3, 2018 Scheduling Order (Paper 13 at 2), Petitioner Breckenridge Pharmaceutical, Inc. (“Petitioner”) hereby provides notice to the Board that Petitioner and Patent Owner Novartis Pharmaceuticals Corporation (“Patent Owner”) have stipulated to modify DUE DATE 2 as follows: DUE DATE 2 (currently set for June 20, 2018) is extended by less than half a day, specifically Patent Owner has agreed that Petitioner may file its Reply to Patent Owner’s Response to Petition and supporting Declaration of Allan J. Pantuck, Ph.D. by 10:00 AM ET on June 21, 2018. In addition, Petitioner and Patent Owner have agreed that service via email of Petitioner’s Reply to Patent Owner’s Response to Petition and supporting Declaration of Allan J. Pantuck, Ph.D. will be made by 8 AM ET on June 21, 2018. Petitioner’s Updated Exhibit List and other exhibits will be timely filed on June 20, 2018.

Patent Owner and Petitioner agree that all other DUE DATES in the
Scheduling Order remain the same.

Dated: June 20, 2018

Respectfully submitted,

By: /Daniel R. Evans/
Daniel R. Evans, Reg. No. 55,868
MERCHANT & GOULD P.C.
191 Peachtree Street, NE, Suite 3800
Atlanta, GA 30303
Main Telephone: 404.954.5100
Main Facsimile: 612.332.9081

*Counsel for Petitioner Breckenridge
Pharmaceutical, Inc.*

CERTIFICATE OF SERVICE

The undersigned hereby certifies that the foregoing Notice of Joint Stipulation to Modify Trial Due Date 2 was served on June 20, 2018, upon the following parties via email:

Nicholas N. Kallas
Fitzpatrick, Cella, Harper & Scinto
1290 Avenue of the Americas
New York, NY 10104-2100
NKallas@fchs.com
ZortressAfinitorIPR@fchs.com

I further certify that a copy of the foregoing Notice of Joint Stipulation to Modify Trial Date 2 was served on June 20, 2018, via email on counsel for Petitioner West-Ward Pharmaceuticals International Limited in *Inter Partes* Review No. 2018-00507 at the following email addresses:

Keith A. Zullo (kzullo@goodwinprocter.com)
Marta E. Delsignore (mdelsignore@goodwinprocter.com)

June 20, 2018

By: /Daniel R. Evans/
Daniel R. Evans, Reg. No. 55,868
MERCHANT & GOULD P.C.
191 Peachtree Street, NE, Suite 3800
Atlanta, GA 30303
Main Telephone: 404.954.5100
Main Facsimile: 612.332.9081

*Counsel for Petitioner Breckenridge
Pharmaceutical, Inc.*